|
Chantix is currently being sold by Pfizer as a smoking cessation drug to help ease the side effects of nicotine withdrawal and help people permanently stop smoking. It was approved by the FDA in May 2006. Chantix is actively being prescribed as a method of nicotine addiction cessation. Severe problems have also begun to surface as reported to the FDA.
The FDA has required Pfizer to add information to the Chantix warning label about a possible increased risk of suicide, suicidal thoughts and abnormal behavior seen among users of the drug.
Some symptoms associated with Chantix our office is currently reviewing include:
- Committed or attempted suicide or had suicidal thoughts.
- Suffered severe physical Injury as a result of sudden abnormal behavior
- Diagnosed with diabetes after starting Chantix
- Developed Stephens Johnson Syndrome due to Chantix
- Suffered severe physical injury or death abnormal physical behavior while on Chantix
Please visit the FDA's website if you have any questions regarding the problems assicated with Chantix
Free Legal Consultation
If you or a loved one has had a severe reaction while taking Chantix, you may have valuable legal rights. To protect these rights, contact Keel O'Malley Tunstall, L.L.P.today by completing the submission form on the left side of this page or by calling 1-888-KEEL-LAW (1-888-533-5529).
Remember, because of statute of limitations, you have a limited time to seek compensation. Contact Keel O'Malley Tunstall, L.L.P.so that we may assist you in protecting your legal rights.
We would be happy to discuss your legal rights with
you on the phone, meet with you in our office or
have one of our staff meet with you at home. There
is NO CHARGE for the initial consultation. If you
cannot come to us, we will GO TO YOU. The members of
our firm look forward to helping you with your products liability claim, call Keel O'Malley Tunstall, L.L.P. Tunstall L.L.P. at
(252) 823-2266 or toll free at 888 - KEEL - LAW, or submit an online
questionnaire.
<< Back to
Practice Areas
Email this Page
|
